Aligos Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company listed on the NASDAQ market in the United States. Founded in 2018 and headquartered in South San Francisco, California, the company was created with a focused mission: to develop best-in-class therapies for liver and viral diseases, especially areas with significant unmet medical need. ([aligos.com](https://aligos.com/about/overview/?utm_source=openai)) From an operating perspective, Aligos is not yet a commercial-stage company. It does not have approved products generating product revenue, so its business model is centered on discovery, preclinical research, clinical development, and the advancement of its drug candidates through regulatory milestones. The company emphasizes a science-driven approach, leveraging deep hepatology and virology expertise to build a differentiated pipeline with potentially improved pharmacologic characteristics. ([aligos.com](https://aligos.com/?utm_source=openai)) Aligos’ pipeline is concentrated in three main areas: chronic hepatitis B, metabolic liver disease including MASH (metabolic dysfunction-associated steatohepatitis), and coronavirus-related programs. Recent company disclosures reference pevifoscorvir sodium, ALG-055009, and ALG-170675 as key development assets. That mix highlights both the specificity of the platform and the binary nature of the investment case: the portfolio targets attractive markets, but each program remains exposed to the typical clinical, regulatory, and manufacturing risks of biotech development. ([investor.aligos.com](https://investor.aligos.com/news-releases/news-release-details/aligos-therapeutics-reports-recent-business-progress-and-6/?utm_source=openai)) In competitive terms, Aligos operates in a crowded landscape that includes large pharmaceutical companies and many specialist biotech peers focused on liver disease and antiviral therapy. Its competitive advantage is therefore not scale, but rather specialization, proprietary scientific know-how, and the possibility of delivering better-tolerated or more effective treatments for chronic diseases that are still difficult to treat. For investors in France, Belgium, or Switzerland, Aligos should be viewed as a high-risk, high-upside clinical biotech rather than a mature operating company. ([aligos.com](https://aligos.com/?utm_source=openai)) Recent developments reinforce that profile. In its first-quarter 2026 update, Aligos reported ongoing progress on pevifoscorvir sodium and its other drug candidates, while also indicating that cash, cash equivalents, and investments were expected to fund planned operations into the third quarter of 2026. That guidance underscores both the importance of near-term clinical readouts and the company’s reliance on prudent capital management. ([investor.aligos.com](https://investor.aligos.com/news-releases/news-release-details/aligos-therapeutics-reports-recent-business-progress-and-6/?utm_source=openai)) Overall, Aligos Therapeutics is a NASDAQ-listed biotechnology company in the United States with a narrowly focused pipeline, no approved commercial products, and a value proposition driven primarily by future clinical data. Its market position is that of a specialized development-stage innovator in liver and viral diseases, where execution and financing will remain central to the investment thesis. ([aligos.com](https://aligos.com/about/overview/?utm_source=openai))